Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.44B 2.13B 2.01B 1.82B 3.41B 234B 3.43B 24B 9.27B 119B 9.17B 8.97B 383B P/E 2026 *
-210x
P/E 2027 * 34.2x
Enterprise Value 2.44B 2.13B 2.01B 1.82B 3.41B 234B 3.43B 24B 9.27B 119B 9.17B 8.97B 383B EV / Sales 2026 *
2.76x
EV / Sales 2027 * 1.78x
Free-Float
95.68%
Yield 2026 *
-
Yield 2027 * -
1 day-2.14%
1 week+0.74%
Current month-5.00%
1 month-12.99%
3 months-3.63%
6 months-17.36%
Current year-15.49%
1 week 40.51
Extreme 40.51
43.4
1 month 40.51
Extreme 40.51
49.82
Current year 40.51
Extreme 40.51
59.68
1 year 40.51
Extreme 40.51
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 21/12/2005
Director of Finance/CFO 67 22/08/2021
Compliance Officer 63 31/12/2011
Director TitleAgeSince
Director/Board Member 64 21/12/2005
Chairman 81 09/08/2016
Director/Board Member 80 15/11/2010
Date Insider Type Main position Quantity % Market Cap. Importance
12/08/26 Exercice

Chief Technology Officer

4,097 0.0073%
12/08/26 Exercice

Chief Financial Officer

3,104 0.0055%
12/08/26 Exercice

Founder

72,340 0.1290%
Change 5-day change 1-year change 3-year change Capi.($)
-2.14%+0.74%-6.25%+43.69% 2.49B
-0.19%+1.49%+81.01%+36.60% 363B
-1.22%-1.37%+20.62%-21.54% 65.62B
+2.53%+5.09%+48.33%+186.72% 12.45B
-0.29%+2.27%-5.37%-16.54% 7.6B
-1.89%-6.83%-27.65%-14.90% 4.49B
-2.06%-3.80%-34.68%+5.56% 4.19B
+1.48%+2.36%-31.20%-13.91% 2.92B
-0.41%-0.71%-28.25%-33.78% 1.93B
-1.69%-3.90%-26.02%-19.02% 1.65B
Average -0.59%+0.23%-0.95%+15.29% 46.64B
Weighted average by Cap. -0.30%+1.36%+66.15%+30.02%

Financials

2026 *2027 *
Net sales 886M 771M 728M 661M 1.24B 84.92B 1.24B 8.71B 3.36B 43.19B 3.33B 3.25B 139B 1.37B 1.19B 1.13B 1.02B 1.92B 131B 1.93B 13.48B 5.21B 66.88B 5.15B 5.04B 215B
Net income -11.54M -10.05M -9.49M -8.62M -16.14M -1.11B -16.22M -113M -43.82M -563M -43.36M -42.4M -1.81B 71.54M 62.29M 58.79M 53.42M 100M 6.86B 101M 703M 272M 3.49B 269M 263M 11.22B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
18/09/26 US$42.00 -2.14% 1,182,187
17/09/26 US$42.92 +3.72% 559,774
16/09/26 US$41.38 +0.24% 787,815
15/09/26 US$41.28 -0.51% 669,223
14/09/26 US$41.49 -0.36% 678,060
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
42.92USD
Average target price
61.75USD
Spread / Average Target
+43.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!